In recent developments, Ascendiant Capital's analyst Edward Woo has made updates to his recommendation for Outlook Therapeutics (OTLK, Financial). According to the latest analyst report dated June 6, 2025, Woo has maintained his "Buy" rating for OTLK, signaling continued confidence in the company's potential performance despite some adjustments.
Significantly, the price target for Outlook Therapeutics (OTLK, Financial) has been lowered from an earlier estimate of $24.00 to a current target of $21.00. This adjustment represents a 12.5% decrease in the expected valuation, reflecting a more cautious outlook on the stock's future price trajectory.
Outlook Therapeutics (OTLK, Financial) continues to be a focus of interest for investors, and Edward Woo's decision to maintain a "Buy" rating suggests a belief in the company's underlying strength and potential for growth, notwithstanding the revised price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Outlook Therapeutics Inc (OTLK, Financial) is $10.50 with a high estimate of $24.00 and a low estimate of $3.00. The average target implies an upside of 460.00% from the current price of $1.88. More detailed estimate data can be found on the Outlook Therapeutics Inc (OTLK) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Outlook Therapeutics Inc's (OTLK, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
